Last reviewed · How we verify
Fluticasone Furoate/GW642444 Inhalation Powder
Fluticasone Furoate/GW642444 Inhalation Powder is a Inhaled corticosteroid/long-acting beta-2 agonist combination Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.
Fluticasone furoate is a corticosteroid that reduces airway inflammation, while GW642444 is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing anti-inflammatory and bronchodilator effects.
Fluticasone furoate is a corticosteroid that reduces airway inflammation, while GW642444 is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing anti-inflammatory and bronchodilator effects. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Fluticasone Furoate/GW642444 Inhalation Powder |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Fluticasone furoate binds to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway inflammation. GW642444 (vilanterol) is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation. The combination provides complementary effects for sustained airway opening and reduced inflammation in obstructive airway diseases.
Approved indications
- Asthma maintenance treatment
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness
Key clinical trials
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma (PHASE3)
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma (PHASE3)
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD (PHASE3)
- Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Furoate/GW642444 Inhalation Powder CI brief — competitive landscape report
- Fluticasone Furoate/GW642444 Inhalation Powder updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Fluticasone Furoate/GW642444 Inhalation Powder
What is Fluticasone Furoate/GW642444 Inhalation Powder?
How does Fluticasone Furoate/GW642444 Inhalation Powder work?
What is Fluticasone Furoate/GW642444 Inhalation Powder used for?
Who makes Fluticasone Furoate/GW642444 Inhalation Powder?
What drug class is Fluticasone Furoate/GW642444 Inhalation Powder in?
What development phase is Fluticasone Furoate/GW642444 Inhalation Powder in?
What are the side effects of Fluticasone Furoate/GW642444 Inhalation Powder?
What does Fluticasone Furoate/GW642444 Inhalation Powder target?
Related
- Drug class: All Inhaled corticosteroid/long-acting beta-2 agonist combination drugs
- Target: All drugs targeting Glucocorticoid receptor; beta-2 adrenergic receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Asthma maintenance treatment
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Compare: Fluticasone Furoate/GW642444 Inhalation Powder vs similar drugs
- Pricing: Fluticasone Furoate/GW642444 Inhalation Powder cost, discount & access